AN OPEN-LABEL RANDOMIZED MULTICENTER PHASE Ib/II TRIAL EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS AND EFFICACY OF MOSUNETUZUMAB (BTCT4465A) IN COMBINATION WITH POLATUZUMAB VEDOTIN IN PATIENTS WITH B-CELL NON-HODGKIN LYMPHOMA

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Non-hodgkin Lymphoma, Unspecified
  • Age: Between 18 - 100 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1) Histologically confirmed FL or DLBCL fro the following diagnoses by 2016 WHO classification of lymphoid neoplasms 2) Must have received at least one prior systemic treatment regimen containing an anti-CD20-directed therapy for DLBCL or FL. Patients must have either relapsed or have become refractory to a prior regimen as defined below. 3) Measurable disease, defined as at least one bi-dimensionally measurable nodal lesion, defined as > 1.5 cm in its longest dimension, or at least one bi-dimensionally measurable extranodal lesion, defined as > 1.0 cm in its longest dimension

You may not be eligible for this study if the following are true:

  • 1) Prior treatment with mosunetuzumab or other CD20-directed bispecific antibodies 2) Prior treatment with polatuzumab vedotin 3) Current > Grade 1 peripheral neuropathy 4) Prior use of any monoclonal antibody, radioimmunoconjugate or antibody-drug conjugate (ADC) within 4 weeks before first dose of study treatment


If you are registered as a volunteer, please login to the dashboard to send referrals.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.